Long-term Vision “Vision 110” is divided into three stages (Stage1: FY2023-FY2025, Stage2: FY2026 -FY2029, and Stage3: FY2030-FY2032). Statement in Vision 110-Stage1- is "transforming into the business structure to realize Vision 110", and the following five business strategies will be promoted with the aim of achieving performance targets and improving support and evaluations from stakeholders.
- 1Strengthening drug discovery capability to create high-value new drugs that meet medical needs
- 2Expansion of development pipeline through in-licensing
- 3Maximization of the ratio of new drugs
- 4Promoting healthcare-related businesses that have synergies with the new drugs business
- 5Building a sustainable corporate foundation
Strategy
New drugs business
Drug Discovery
Reorganization
Creation of new drugs from long-term perspective
Strengthen the drug discovery capability to create high-value new drugs that meet medical needs
- Try for drug innovation through new drug discovery strategies
Development
Investment of resource
Enhancement of development pipeline
Expansion of development pipeline through in-licensing
- Significantly strengthen in-licensing ability
- Promote DTx development
Marketing, SCM, Reliability Assurance
Driving force of revenue
Maximization of profitability
Maximization of the ratio of new drugs
- Maximize the extension of new drugs
- Ensure the stable supply of high-quality drugs
Healthcare-related business
GE business
- Achieve sustainable growth in the generic drugs business
- Strengthen production capacity for drugs and reduce manufacturing costs
Other business
- Promote infectious disease-related business